跳到正文
原文
The Lancet· Cinta Moraleda, Alfredo Tagarro, Sara Domínguez-Rodríguez, Victor Musiime, Hilda Mujuru, Chishala Chabala, Tisungane Mvalo, Pui-Ying Iroh-Tam, Justina Bramugy, Lola Madrid, Jahit Sacarlal, Alfeu Passanduca, Muhammad Sidat, Uneisse Cassia, Hellen Tukamuhebwa Aanyu, Abner Tagoola, Constantine Mutata, Bwendo Nduna, Chimwemwe Chawinga, Lughano Ghambi, Matthew Bates, Sheila Fernández-Luis, Amir Seni, Merunissa Gafur, Damalie Nalwanga, Denis Nansera, Mutsa Bwakura-Dangarembizi, Natasha Namuziya, Franklyn Nkongho Egbe, John Tembo, Álvaro Ballesteros, Raoul Moh, Lilit Manukyan, David Lora, Olivier Marcy, Tom G Jacobs, David Burger, Quique Bassat, Valeriane Leroy, Alessandra Nardone, W Chris Buck, Pablo Rojo, Empirical Clinical Trial Group·· 2026-07-18精选AI 评分58

非洲HIV感染重症肺炎婴儿经验性使用缬更昔洛韦的多中心随机对照试验

[Articles] Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial

AI 导读

一项在非洲开展的多中心、开放标签、析因设计、随机对照优效性试验显示,对HIV感染并因重症肺炎住院的婴儿经验性使用缬更昔洛韦,与单用标准治疗或标准治疗联合经验性抗结核治疗相比,死亡风险似乎更低,且未见明显相关危害。该结果发表于《柳叶刀》,作者为Empirical Clinical Trial Group等多国研究团队。

推荐理由

摘要给出了一项多中心随机对照试验在非洲HIV感染婴儿重症肺炎中的经验性抗病毒治疗结果,读者可据此了解该干预与标准治疗在死亡风险上的差异。

来源:The Lancet · thelancet.com